Most Read Articles
3 days ago
The appropriate cutoff value in predicting combined cardiovascular outcomes in patients with type 2 diabetes (T2D) is 125 mm Hg for home morning systolic blood pressure (MSBP), suggests a new study.
06 Apr 2018

Female patients with coronary artery disease (CAD) have greater regression of coronary atherosclerosis than male patients despite a lower plaque burden at baseline, data from the GLAGOV trial have shown.

26 Apr 2018
Transcatheter aortic valve replacement (TAVR) in severe symptomatic aortic stenosis (AS) patients is superior to conventional surgical aortic valve replacement (SAVR) in terms of reducing life-threatening bleeding, new-onset atrial fibrillation and acute kidney injury, a recent meta-analysis has found.
Pearl Toh, 2 days ago
Whether the 2017 ACC/AHA* blood pressure (BP) guidelines should be adopted in Asian countries was the topic of a much-anticipated discussion here at the Asian Pacific Society of Cardiology (APSC) Congress 2018 in Taiwan last week.

Favourable clinical outcomes, lower sICH with low-dose alteplase in patients with prior antiplatelet therapy

Audrey Abella
17 Aug 2017

The use of low-dose intravenous (IV) alteplase may be associated with more favourable clinical outcomes and lower risk of symptomatic intracerebral haemorrhage (sICH) in thrombolysis-treated acute ischaemic stroke patients who previously received antiplatelet therapy (APT) compared with the standard dose, according to the ENCHANTED* trial.

This multicentre, prospective, blinded-end point trial included 3,285 patients (mean age 66.6 years, 38 percent women). The 752 patients who reported prior APT use were randomized to receive low-dose (0.6 mg/kg, n=407) or standard-dose (0.9 mg/kg, n=345) IV alteplase within 4.5 hours of symptom onset.

Although not significant, low-dose alteplase resulted in a more favourable 90-day clinical outcome than standard-dose alteplase in patients with APT history vs those without prior APT based on mRS (modified Rankin Scale) scores 2–6 (odds ratio [OR], 0.84 vs OR, 1.16; p-trend=0.053), mRS scores 3–6 (OR, 0.80 vs OR, 1.10; p-trend=0.065), or ordinal mRS shift (OR, 0.76 vs OR, 1.07; p interaction=0.023). [Stroke 2017;48:1877-1883]

Based on the SITS-MOST** criteria, prior APT use was associated with an increased sICH risk (adjusted OR, 1.82, 95 percent CI, 1.00–3.30; p=0.051), which decreased in patients given low-dose vs standard-dose alteplase (OR, 0.38, 95 percent CI, 0.14–1.02).

“Patients on prior APT … are at significantly higher risk of sICH and poor outcome compared with other patients who receive alteplase,” said the researchers. “[T]his may be considered an important treatment option in such patients.”

The researchers highlighted that while the numbers are ‘too small’ to offer a reliable risk assessment based on varying doses of alteplase, some study protocols have recommended the avoidance of APT for at least 24 hours after alteplase use. [Stroke 2013;44:870-947; Cochrane Database Syst Rev 2014;7:CD000213]

Overall, although nonsignificant, the results suggest a trend towards better clinical outcomes with low-dose vs standard-dose alteplase, said the researchers, who called for randomized trials to elucidate the effects of low-dose and standard-dose alteplase in patients with APT history.

The potential benefits of low-dose alteplase in patients with high sICH risk should also be further investigated, they added.

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
3 days ago
The appropriate cutoff value in predicting combined cardiovascular outcomes in patients with type 2 diabetes (T2D) is 125 mm Hg for home morning systolic blood pressure (MSBP), suggests a new study.
06 Apr 2018

Female patients with coronary artery disease (CAD) have greater regression of coronary atherosclerosis than male patients despite a lower plaque burden at baseline, data from the GLAGOV trial have shown.

26 Apr 2018
Transcatheter aortic valve replacement (TAVR) in severe symptomatic aortic stenosis (AS) patients is superior to conventional surgical aortic valve replacement (SAVR) in terms of reducing life-threatening bleeding, new-onset atrial fibrillation and acute kidney injury, a recent meta-analysis has found.
Pearl Toh, 2 days ago
Whether the 2017 ACC/AHA* blood pressure (BP) guidelines should be adopted in Asian countries was the topic of a much-anticipated discussion here at the Asian Pacific Society of Cardiology (APSC) Congress 2018 in Taiwan last week.